Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study.
D000368:Aged; D006585:Altretamine / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D014227:Triazines / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D014227:Triazines; D004317:Doxorubicin; D003520:Cyclophosphamide; D006585:Altretamine; D005472:Fluorouracil